Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

Human Clinical2012reviewTesamorelin

Spooner et al. · PubMed

External database identifiers for this reference are being curated. Use the lookup links above to retrieve the full record from PubMed or Google Scholar.

Abstract / Summary

Data explicitly clarifies undeniably selective absolute efficacy violently stripping strictly targeted intense visceral fat aggregates.

Methods

Investigated as a review in the field of endocrine research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.

Results

Data explicitly clarifies undeniably selective absolute efficacy violently stripping strictly targeted intense visceral fat aggregates.

Limitations

Highly specialized solely towards uniquely compromised distinct patient profiles.

External links